Introduction
Lepromatous leprosy patients present a wide clinical spectrum, complicated further by their tendency to develop "reactions" while on treatment. These reactions vary in severity from acute brief episodes to recurrent and chronic exacerbations. While mild reactions are easily controlled with simple drugs, such as aspirin, chloroquine, parenteral antimony, and indomethacin, patients with severe erythema nodosum leprosum syndrome who are very ill and toxic respond only to large doses of corticosteroid (Jopling, 1964; Karat et al., 1970) . Such doses produce serious complications and have no antibacterial effect. Therefore search for an effective antileprosy drug which can suppress episodes of reaction continues.
Clofazimine (Lamprene; G30.320; B.663), a riminophenazine derivative, is reported to have an anti-inflamunatory effect (Browne, 1965; Hastings and Trautman, 1968; Imkamp, 1968) in addition to specific activity against the leprosy bacillus (Browne and Hogerzeil, 1962a, 1962b; Williams et al., 1965; Pettit and Rees, 1966; Pettit et al., 1967) . It is also effective in suppressing further exacerbations (British Medical 7ournal, 1969 Material and Methods Clofazimine 100 mg. three times a day for 12 weeks was compared with prednisolone given according to the following schedule: 10 mg. thrice a day for the first week, 10 mg. twice a day for the second week, 5 mg. thrice a day for the third week, 5 mg. twice a day for the fourth week, and 5 mg. once a day for the subsequent eight weeks.
Patients who had a history of three or more severe reactions and whose current reaction was 3 + or 4 + (see Table I ), which could not be controlled by antimony, aspirin, or chloroquine, were included in this series. Patients who were known to have radiologically proved peptic ulcer, those with intercurrent acute infections, and those with tuberculosis or malignant lesions were excluded from the trial. Patients satisfying the criteria for inclusion were assigned to clofazimine or to prednisolone according to the list of random allocations prepared earlier and kept confidential at the pharmacy. Packages of these two drugs labelled serially 1, 2, 3, etc., were given to patients as they entered into the trial.
The past history, the present complaints, the findings at detailed physical examination, and the results of laboratory investigation of each patient were recorded on a special form. Twelve patients in each of the two drug groups were observed for more than four months. These groups were similar in terms of sex, age distribution, and duration of leprosy. There was no difference in past history of reactions (number and severity) and severity of erythema nodosum leprosum lesions at entry into the trial (Table II) . The side-effects observed in the groups are shown in The present study shows that clofazimine in a dose of 100 mg. three times a day is an effective treatment for severe erythema nodosum leprosum reaction in lepromatous leprosy and that it improves liver function in these chronically debilitated patients as judged by an appreciable rise in serum albumin levels. We were unable to find any deleterious effects of clofazimine on the cardiovascular, respiratory, alimentary, genitourinary, and nervous systems under the conditions of the trial at a dose of 300 mg. a day as judged by clinical and laboratory assessments.
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